Scil Proteins to manufacture Reteplase for Actavis
Reteplase is the active ingredient in heart attack drug Rapilysin
Scil Proteins, a privately owned German biotech company specialising in the development of recombinant proteins, has signed a supply agreement with Swiss generics firm Actavis, for the future manufacturing of Reteplase. Financial terms were not disclosed.
Reteplase is a recombinant protein and the active ingredient in the medicinal product Rapilysin for thrombolytic treatment of myocardial infarction. Scil Proteins originally signed an agreement with Roche in June 2008 for process transfer and manufacture of Reteplase. The protein has a demanding production process requiring considerable experience in protein refolding. Actavis owns the rights to the Reteplase production process and on Rapilysin for distribution in Europe and worldwide, excluding the US and Canada.
As well as the previous agreement with Roche, this new agreement adds to Scil Proteins’ portfolio of contract development and manufacturing clients.